GIPR and Hyperglycemia: Adding a polyethylene glycol tail to enhance bioavailability and half-life (PEGylated GIPR–GLP-1R co-agonist) of GIPR/GLP-1R dual agonism lowered body weight by 26.9%, whereas the acylated co-agonist lowered it by 31.4%, and liraglutide by 15.6%, with all three agonists similarly lowering food intake and improving dyslipidemia and hyperglycemia (Finan et al. 2013).